Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus Anlotinib in Advanced Cholangiocarcinoma
NCT03996408Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in cholangiocarcinoma (CCA), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03996408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03996408.